Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

The company said it remains focused on global development of crofelemer powder for oral solution for short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). It is targeting a mid-2027 NDA filing for MVID; the update provides a development timeline but no clinical results.